Fusion Antibodies plc

5.25pAs of Sun 8 Nov 2026, 12:00 UTC
LSE:FABHealthcare
Ctry United Kingdom
PE (Fwd) •••
TSR 9Y CAGR (34.18%)
Div yield —
ROE (96.64%)
Biotechnology
Beta (5Y) 1.39
PE TTM —
TSR TTM (61.11%)
Mkt cap £6.571M
ROIC (121.87%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
5.91p
12.67%
(24.75%)
Hold 9|6|8|8|5
3Q26
4Q26
1Q27
2Q27
Earnings per share£
0.07
0.07
0.08
0.08
18.79%
21.61%
31.48%
27.73%
Revenue£M
0.371
0.380
0.391
0.400
12.48%
10.63%
8.37%
5.27%
Peers (US$8.839M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
7.669
(0.041)
(0.045)
EBIT/Intx
1.668
0.733
0.637
Own earn%
(98.93)
(27.18)
(36.53)
Sh yield%
41.24
70.48
70.05
Owners
Insiders/Inst%
9.38
48.35
Short interest%
2.44
SBC / revenue%
1.95
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
4
Op margin range%
30–40
$1 testx
—
Incr. ROIC%
24